Liporosa (Ezetimibe, Rosuvastatin Zinc)

Liporosa acts on lipid metabolism pathways to lower abnormal cholesterol levels.

• Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol.
• Mixed dyslipidemia: reduces both LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol.
• Primary prevention of cardiovascular disease: helps decrease the risk of heart attack and stroke in patients with elevated lipid profiles.

• Ezetimibe blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Rosuvastatin zinc inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol synthesis. The combined effect decreases circulating LDL‑cholesterol and improves overall lipid profile.

Liporosa may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Abdominal pain: discomfort in the stomach area.
• Diarrhea: loose stools occurring intermittently.
• Muscle aches: mild myalgia without weakness.
• Elevated liver enzymes: mild increase in ALT/AST.
• Nausea: feeling of queasiness.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with dark urine.
• Acute liver injury: marked elevation of liver enzymes with jaundice.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Myopathy: muscle weakness with elevated CK levels.
• Pancreatitis: abdominal pain with elevated pancreatic enzymes.
• Hepatotoxicity: liver failure requiring medical intervention.

Before initiating Liporosa, clinicians should evaluate patient-specific risk factors and monitor relevant laboratory parameters.

• Liver function monitoring: check ALT/AST before treatment and periodically thereafter.
• Muscle symptom assessment: inquire about unexplained muscle pain or weakness.
• Renal function evaluation: adjust use in patients with severe renal impairment.
• Drug interaction review: assess concomitant medications that may increase statin exposure.
• Pregnancy and lactation: avoid use unless clearly indicated by a physician.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Liporosa can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Cyclosporine: markedly increases rosuvastatin plasma concentrations.
• Gemfibrozil: raises risk of myopathy and rhabdomyolysis.
• Strong OATP1B1 inhibitors (e.g., rifampin): elevate rosuvastatin levels.

Moderate Interactions (Monitor Closely)

• Amlodipine: may increase rosuvastatin exposure modestly.
• Antacids containing aluminum or magnesium: can reduce ezetimibe absorption.
• Niacin: may increase risk of liver enzyme elevation.
• Fibrates (e.g., fenofibrate): monitor for additive lipid‑lowering effect and muscle toxicity.
• Digoxin: observe for potential increased serum concentrations.